Esperante Ventures is a globally active life sciences corporate venture capital investor. It has to date invested EUR 500k–5m per transaction in mid-to-late stage therapeutics and commercial-stage diagnostics, in syndication with co-investors. Highlights: International portfolio of companies across oncology, immunology, infectious diseases, CNS, ophthalmology, hearing disorders, haematology and molecular diagnostics. Major portfolio fundraisings: Cara Therapeutics $128m, Atox Bio $56m. 5 profitable exits; fund currently in profit. Notable outcomes: Cara Therapeutics (stock sales), Pinnacle Biologics (sale to Concordia), Thiakis (sale to Wyeth), Haemostatix (sale to Ergomed) and Versantis (sale to Genfit). 4 public listings: Cara Therapeutics (NASDAQ, whilst Director pre and post IPO, Altimmune (NASDAQ), Medicenna Therapeutics (TSX) and Silexion (NASDAQ). Active portfolio: Acousia Therapeutics, Altimmune, Pneumagen, Silexion Therapeutics, Spiral Therapeutics, Kiyatec and Oxford Cancer Biomarkers.
Looking for a particular Esperante employee's phone or email?
Esperante Questions
The Esperante annual revenue was $215000 in 2026.
1 people are employed at Esperante.
Esperante is based in Hoofddorp, North Holland.
The NAICS codes for Esperante are [325, 32, 32541, 3254, 325413].
The SIC codes for Esperante are [28, 283].
Top Esperante Employees
Related Companies
